Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 879 results found since Jan 2013.

PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Authors: Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib or rucaparib, have shown treatment efficacy in BRCA1/2-deficient tumors. However, since PARP inhibitors (PARPi) mainly modulate the activation of PARP but not its expression, whether small interfering RNA (siRNA) specific to PARP has the same function as PARPi has not been well defined. In the present study it was demonstrated that PARP1-siRNA could reduce prostate cancer (PCa) cell progression regardless of the BRCA1/2 mutation. PARP1 silencing could significantly inhibi...
Source: Oncology Reports - February 4, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer
Conclusion: PSMAb mediated TRIM24 siRNA delivery platform could significantly inhibit cell proliferation, colony-formation, and invasion in PSMA+ CRPC in vitro and suppressed tumor growth and bone loss in PSMA+ CRPC xenograft and bone metastasis model.
Source: Theranostics - June 13, 2019 Category: Molecular Biology Authors: Sheng-Jia Shi, Li-Juan Wang, Dong-Hui Han, Jie-Heng Wu, Dian Jiao, Kai-Liang Zhang, Jiang-Wei Chen, Yu Li, Fa Yang, Jing-Liang Zhang, Guo-Xu Zheng, An-Gang Yang, Ai-Zhi Zhao, Wei-Jun Qin, Wei-Hong Wen Tags: Research Paper Source Type: research

siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer.
CONCLUSIONS: LNP siRNA can silence target genes in vivo and enable inhibition of traditionally non-druggable genes like CLU and other promising co-targeting approaches in ENZ-R CRPC therapeutics. PMID: 26106075 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 23, 2015 Category: Cancer & Oncology Authors: Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave ME Tags: Clin Cancer Res Source Type: research

Dendrimer Nanovectors for SiRNA Delivery.
Abstract Small interfering RNA (SiRNA) delivery remains a major challenge in RNAi-based therapy. Dendrimers are emerging as appealing nonviral vectors for SiRNA delivery thanks to their well-defined architecture and their unique cooperativity and multivalency confined within a nanostructure. We have recently demonstrated that structurally flexible poly(amidoamine) (PAMAM) dendrimers are safe and effective nanovectors for SiRNA delivery in various disease models in vitro and in vivo. The present chapter showcases these dendrimers can package different SiRNA molecules into stable and nanosized particles, which prote...
Source: Mol Biol Cell - October 17, 2015 Category: Molecular Biology Authors: Liu X, Peng L Tags: Methods Mol Biol Source Type: research

Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
CONCLUSION: Microbubble-liposome complex can effectively target prostate cancer cells, enabling intracellular delivery of the treatment agents with the use of ultrasound. Ultrasound and MLC-mediated delivery of survivin-targeted siRNA and doxorubicin can induce prostate cell apoptosis and block survivin expression in vitro and in vivo. PMID: 27390541 [PubMed - in process]
Source: Korean Journal of Radiology - July 10, 2016 Category: Radiology Tags: Korean J Radiol Source Type: research

Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
In this study, AuNPs capped with polyethylenimine (PEI) and PEGylated anisamide (a ligand known to target the sigma receptor) have been developed to produce a range of positively charged anisamide-targeted PEGylated AuNPs (namely Au-PEI-PEG-AA). The anisamide-targeted AuNPs effectively complexed siRNA via electrostatic interaction, and the resultant complex (Au110-PEI-PEG5000-AA.siRNA) illustrated favourable physicochemical characteristics, including particle size, surface charge, and stability. In vitro, anisamide-targeted AuNPs selectively bound to human prostate cancer PC-3 cells, inducing efficient endosomal escape of ...
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 16, 2019 Category: Drugs & Pharmacology Authors: Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O'Driscoll CM, Guo J Tags: Eur J Pharm Biopharm Source Type: research

GSE194248 Human prostate cancer cells (VCaP and AIVCaP): siAR alone (single siRNA) vs. siAR plus OPRK1 (combo-siRNA)
Contributors : Yuki Makino ; Takashi KobayashiSeries Type : Expression profiling by arrayOrganism : Homo sapiensThrough comparative genomics using PDX models of androgen-dependent (AD) and castration-resistant (CR) tumors, we identify opioid receptor kappa 1 (OPRK1) as being associated with castration-resistance. Loss of OPRK1 function delays castration-resistance and inhibits castration-resistant growth of prostate cancer cells in culture and in vivo, suggesting OPRK1 as a therapeutic target.To gain insight with regard to biological function of OPRK1 under androgen-depleted condition, we set up two distinct comparisons us...
Source: GEO: Gene Expression Omnibus - April 3, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo.
Abstract Specific and efficient delivery of siRNA into intended tumor cells remains as a challenge, even though RNAi has been exploited as a new strategy for prostate cancer therapy. This work aims to address both specificity and efficiency of SURVIVIN-siRNA delivery by constructing a therapeutic complex using combinatorial strategies. A fusion protein STD was first expressed to serve as a backbone, consisting of streptavidin, a cell-penetrating peptide called Trans-Activator of Transcription (TAT) and a double-stranded RNA binding domain. A biotinylated Prostate Specific Membrane Antigen (PSMA) specific aptamer A...
Source: Cancer Biology and Therapy - March 8, 2016 Category: Cancer & Oncology Authors: Diao Y, Liu J, Ma Y, Su M, Zhang H, Hao X Tags: Cancer Biol Ther Source Type: research

Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates
We report that such coupling generates monomeric antibody–siRNA conjugates (ARCs) that retain antibody and siRNA activities. To broadly assess this technology, we generated a battery of THIOMABs against seven targets that use multiple internalization routes, enabling systematic manipulation of multiple parameters that impact delivery. We identify ARCs that induce targeted silencing in vitro and extend tests to target prostate carcinoma cells following systemic administration in mouse models. However, optimal silencing was restricted to specific conditions and only observed using a subset of ARCs. Trafficking studies ...
Source: Nucleic Acids Research - January 23, 2015 Category: Research Authors: Cuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S. J., Gesch, J., Davis, D., van Brabant Smith, A., Leake, D., Vandlen, R., Siebel, C. W. Tags: RNA Source Type: research

Influence of suppression of CapG gene expression by siRNA on the growth and metastasis of human prostate cancer cells.
This study investigated CapG gene expression in prostate cancer cell lines; in addition, we explored the effects of CapG suppression on DU145 cell growth, and the underlying mechanism with which CapG affects DU145 cell growth and invasiveness. The expression of CapG and 18 related genes in DU145 cells was analyzed by flow cytometry, quantitative polymerase chain reaction (qPCR), CCK8 assay, western blot, and the trans-well assay. DU145 cells were transfected with designed small interfering RNA (siRNA). CapG expression was quantified by qPCR and western blot. DU145 cell proliferation and invasiveness was analyzed using the ...
Source: Cell Research - December 7, 2015 Category: Cytology Authors: Li BK, Guo K, Li CY, Li HL, Zhao PP, Chen K, Liu CX Tags: Genet Mol Res Source Type: research

Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA
In this study, we demonstrated a novel strategy to construct negatively charged and ultrasound (US)-responsive O-carboxymethyl chitosan (O-CMS) NDs as a siRNA targeted delivery system through three-way junction of bacteriophage phi29 DNA packaging motor (3WJ-pRNA) nanotechnology. 39nt A10-3.2 aptamer targeting prostate specific membrane antigen (PSMA) and 21nt siRNA against cationic amino acid transporter 1 (siCAT-1) were annealed to 3WJ-pRNA scaffold via complementation with an extended sequence. The cholesterol molecule attached to one branch facilitates the 3WJ-pRNA nanoparticles anchoring onto NDs. The desired O-CMS ND...
Source: Drug Delivery - January 17, 2022 Category: Drugs & Pharmacology Authors: Lu Guo Dandan Shi Mengmeng Shang Xiao Sun Dong Meng Xinxin Liu Xiaoying Zhou Jie Li Source Type: research

Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Abstract We have previously described the development of novel sterically stabilized F3-targeted pH-sensitive liposomes, which exhibited the ability to target both cancer and endothelial cells. Herein, the therapeutic potential of those liposomes was assessed upon encapsulation of a siRNA against a well-validated molecular target, PLK1. Treatment of prostate cancer (PC3) and angiogenic endothelial (HMEC-1) cells with F3-targeted liposomes containing anti-PLK1 siRNA resulted in a significant decrease in cell viability, which was mediated by a marked PLK1 silencing, both at the mRNA and protein levels. Furthermore, ...
Source: European Journal of Pharmaceutics and Biopharmaceutics - May 7, 2013 Category: Drugs & Pharmacology Authors: Gomes-da-Silva LC, Ramalho JS, Pedroso de Lima MC, Simões S, Moreira JN Tags: Eur J Pharm Biopharm Source Type: research

ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells.
We report here for the first time the ESM-1 targeting in PC-3 cells, which resulted in decreased migration, which may be related, at least in part, to decreased expression of the angiogenic CXCL3 chemokine, whose expression was found to be reduced in ESM-1-siRNA transfected cells. Additional studies are required to ascertain the biological role of ESM-1 in prostate cancer cells and the link with the expression of CXCL3. PMID: 28533735 [PubMed - in process]
Source: International Journal of Biomedical Science - May 25, 2017 Category: Biomedical Science Tags: Int J Biomed Sci Source Type: research

Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1).
In this study, it has been shown that PCL can encapsulate RAP with high loading efficiencies, and PAsp(DET) can successfully interact with siRNA for efficient transfection/knockdown with negligible cytotoxicity. The enhanced therapeutic efficacy of RAP/siYB-1 micelles was demonstrated in cell cultures and in a PC3 xenograft nude mouse model of human prostate cancer. Herein, we demonstrate that trilayer micelles are a promising approach to improve the simultaneous delivery of combination siRNA/drug therapies. PMID: 23768780 [PubMed - as supplied by publisher]
Source: Biomaterials - June 11, 2013 Category: Materials Science Authors: Zeng S, Xiong MP Tags: Biomaterials Source Type: research